Lava Therapeutics B.V. (spin-off Amsterdam UMC, location VUmc) announced that it has entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer. The collaboration was facilitated by Johnson & Johnson Innovation.
“We are excited to enter into this collaboration with Janssen, a global innovator and leader in the development of new medicines,” said Stephen Hurly, chief executive officer of Lava Therapeutics. “We strongly believe in the strength of our bispecific gamma-delta T cell engager platform and are committed to creating highly potent, target-specific therapeutics with increased durability and safety over current T cell-based approaches.”
Under the terms of the agreement, Lava Therapeutics will perform discovery and product development activities, and is eligible to receive an undisclosed financial package consisting of an upfront payment and potential development and commercial milestones, and future tiered royalties.
Lava Therapeutics, B.V., is developing a proprietary bispecific antibody platform that engages gamma-delta T cells for the treatment of hematological and solid cancers. The company’s first-in-class immuno-oncology approach activates Vγ9Vδ2 T cells upon binding to membrane-expressed tumor targets. Lava was founded in 2016 based on intellectual property originating from the Amsterdam University Medical Center, and is backed by Lupus Ventures, Biox Biosciences, Versant Ventures, Gilde Healthcare and MRL Ventures Fund. The company has established a highly experienced antibody research and development team located in Utrecht, the Netherlands (headquarters) and Philadelphia. For more information, please visit www.lavatherapeutics.com.
The UvA, VU, Amsterdam UMC, HvA and ROM InWest have just signed a collaboration agreement today on 12 March 2024. The parties are intensifying their collaboration for more entrepreneurship and innovation in Life Science Health (LSH). “Because of its knowledge institutions and the Netherlands’ largest academic hospital, Amsterdam is home to the top of Dutch […]
NewsIn the Life Sciences & Health round, 14 researchers have been selected for the Faculty of Impact programme for two years of intensive and personal guidance in entrepreneurship, intellectual property and investment. Four Amsterdam based researchers have been selected as well: Anouk Post (VU), Olivier Lugier (UvA), Felix Paulußen (VU) and Ewelina Weglarz-Tomczak (UvA). A […]
NewsThe Dutch chemical industry grapples with pressing challenges, such as green energy supply stability, the need for enhanced facilities and infrastructures to facilitate efficient scaling up of chemical processes, and the complexities surrounding material transition. These challenges underscore the imperative for increased innovation and robust public-private cooperation. Marco Tibaldi, from the Amsterdam Chemistry Network, explains […]
News